

The Mosaic Landscape of Prescription Stimulant Misuse and Abuse

Janetta L. Iwanicki, MD
Chief Scientific Officer
Rocky Mountain Poison & Drug Safety


VA Stimulant Safety Summit, February 24, 2021

Conflict of Interest Statement

- RADARS System is the property of Denver Health and Hospital Authority, a political subdivision of the State of Colorado
- Many manufacturers of prescription opioids or stimulants as well as federal agencies subscribe to RADARS System. No company has special privileges.
- Subscribers receive information, but do not participate in developing the System, data collection, or analysis of the data. They do not have access to the raw data.
- Employees are prohibited from having personal financial relationships with any company
- Future work on this topic is funded by FDA BAA Grant 2020-2021 #145

Prescription Stimulants: Why Should We Care?


- Increasing prescribing, even over past 5 years



Source: FDA analysis of IQVIA National Prescription Audit 2019

Prescription Stimulants: Why Should We Care?


- Adolescent and young adult age groups most impacted by both use and non-medical use (NMU)




Source: FDA-generated figure from the National Survey on Drug Use and Health, 2018

Prescription Stimulants: Why Should We Care?

- Increasing stimulant mortality, includes prescription products




What is Mosaic Research?




Zooming in by Prescription Stimulant Active Pharmaceutical Ingredients (APIs)


Stimulant Prescribing is Different by API



RADARS Drug Diversion Program Prescription Stimulant Diversion Trending Up




RADARS Poison Center Program Prescription Amphetamine Intentional Exposures Trending Up




RADARS NMURx Survey

Rx Stimulant Nonmedical Use Impacts Large Population




Zooming in by Routes of Use

RADARS NMURx Survey, Non-Oral Routes of Rx Stimulant NMU Are Fairly Common



RADARS NMURx Survey, Non-Oral Routes of Rx Stimulant NMU Differ by API



Putting It All Together

- Mosaic data should be triangulated to form more complete picture of trends
- Prescription stimulant prescribing continues to increase
- Large portion of the US population is impacted by prescription stimulant NMU

Putting It All Together

- Non-oral stimulant NMU is fairly common and should be studied further
- Need product-specific data to evaluate risks
 - API differences
 - Immediate vs extended release
 - Unique formulations
- Relationship between prescription and illicit stimulants not yet known, but mortality trends are concerning

Thank you!

Janetta L. Iwanicki, MD

Chief Scientific Officer

Rocky Mountain Poison & Drug Safety

Email Janetta.Iwanicki@RMPDS.org

Twitter [@DrJ4747](https://twitter.com/DrJ4747)